Article

Pharmaceutical Strategies to Make Better Drugs for Nonalcoholic Fatty Liver Disease Therapy

2023-06-15

Abstract excerpt

Nonalcoholic fatty liver disease (NAFLD) has become globally prevalent and is the leading cause of chronic liver disease. Although NAFLD is reversible in the early stage without medical intervention, the condition could be sequentially worsened to nonalcoholic steatohepatitis (NASH) and, in the end, cirrhosis and hepatic cancer. The progression of NAFLD is related to various factors such as genetics, pre-disposed...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b7616b51-d082-5971-9e0c-a30013b64a1c
DOI: 10.20944/preprints202306.1108.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Pharmaceutical Strategies to Make Better Drugs for Nonalcoholic Fatty Liver Disease TherapyDOI 10.20944/preprints202306.1108.v1Read

Present and future therapeutic strategies in non-alcoholic fatty liver disease.Semantic proximity Read

Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches.Semantic proximity Read

Personalized therapy when tackling nonalcoholic fatty liver disease: a focus on sex, genes, and drugs.Semantic proximity Read

Mechanisms of Cynarine for treatment of Non-alcoholic Fatty Liver Disease Based on the Integration of Network Pharmacology, Molecular Docking and Cell ExperimentSemantic proximity Read

Non-alcoholic fatty liver disease.Semantic proximity Read

Non-alcoholic Fatty Liver Disease (NAFLD) Management in the CommunitySemantic proximity Read

Non-alcoholic fatty liver disease: what the clinician needs to know.Semantic proximity Read

Advanced Strategies in Enhancing the Hepatoprotective Efficacy of Natural Products: Integrating Nanotechnology, Genomics, and Mechanistic InsightsSemantic proximity Read

Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.Semantic proximity Read

Identify Key Active Ingredients and Molecular Mechanisms of Jiangzhi Decoction on Non-alcoholic Fatty Liver Disease by Network Pharmacology AnalysisSemantic proximity Read

Advancements in Understanding and Treating NAFLD: A Comprehensive Review of Metabolic-Associated Fatty Liver Disease and Emerging TherapiesSemantic proximity Read

Obesity and the liver: nonalcoholic fatty liver disease.Semantic proximity Read